CNSY Cerenome, Inc.
Company Analysis
Latest News
🔴 Cerenome is trading 5.66% down today amid broader market weakness after the Fed rate hike
Cerenome is trading 5.66% down now at $2.00 after broad market weakness following the Federal Reserve’s 25-basis-point rate hike and hawkish outlook. - The...
🟢 Cerenome is trading 5.3% up in pre-market with no clear company-specific catalyst identified
Cerenome is trading 5.3% up now at $2.23 after no clear company-specific catalyst was identified for September 16, 2026. - The latest notable disclosure was a...
🔴 Cerenome is trading 5.3% down today amid broader market weakness and rate uncertainty
Cerenome is trading 5.3% down at $2.20, with broader market weakness and elevated rate uncertainty the most likely context. - The price declined from $2.33 on...
Cerenome, Inc. Announces up to $21.3M Senior Secured Convertible Note Financing
Cerenome, Inc. has entered into a securities purchase agreement with an institutional investor to raise up to $21.28 million through the issuance of senior...
🟢 Cerenome is trading 8% up in pre-market with no company-specific catalyst identified
Cerenome is trading 8.02% up at $2.69 after rising from the September 9 close of $2.49; the catalyst remains unclear. - No company-specific announcement,...
🔴 Cerenome is trading 5% down today as insurance-coverage concerns weigh on healthcare stocks
Cerenome is trading 5% down at $2.56 as insurance-coverage concerns weigh on healthcare stocks; no new company-specific announcement was identified for...
🔴 Cerenome is trading 5.54% down today amid broader market weakness
Cerenome is trading 5.54% down at $2.81, amid broader market weakness with no clear company-specific catalyst identified for September 4, 2026. - Opened below...
🔴 Cerenome is trading 6% down in pre-market with no clear overnight catalyst identified
Cerenome is trading 6.12% down at $2.76 after closing at $2.94 on September 2, 2026, with no clear overnight catalyst identified. - No new company-specific...
🟢 Cerenome is trading 5.17% up today with no company-specific catalyst identified
Cerenome is trading 5.17% up at $2.85, with no company-specific announcement identified for September 2, 2026. - CNBC reports no recent news for the...
🟢 Cerenome is trading 7% up in pre-market; catalyst unclear
Cerenome is trading 7.01% up now at $2.90, with no company-specific announcement identified for September 2, 2026. - CNBC reports no recent news for the...
🔴 Cerenome is trading 5.1% down today amid broader market risk-off pressure
Cerenome is trading 5.1% down at $2.67 as broader risk-off conditions pressure equities. - No new company-specific announcement was identified for September...
🔴 Cerenome is trading 6.23% down today
Cerenome is trading at $2.86, down -6.23%, with no company-specific announcement identified for August 31, 2026. - The latest investor-relations release is...
🟢 Cerenome is trading 5.6% up today as broader markets strengthen
Cerenome is trading at $3.19, up +5.63%, most likely reflecting broad market strength rather than a confirmed company-specific catalyst. - S&P 500 and Nasdaq...
🟢 Cerenome is trading 5% up today as softer confidence data supports rate-cut hopes
Cerenome is trading 5% up at $3.11, with the move appearing consistent with broader risk-on sentiment. - No new company-specific announcement dated August 25,...
🔴 Cerenome is trading 5.3% down today; immediate catalyst unclear
Cerenome is trading 5.3% down at $3.02, with the immediate catalyst unclear. - No company-specific announcement has been explicitly linked to the August 20,...
🔴 Cerenome is trading 10% down today after Q2 results missed EPS and revenue estimates
Cerenome is trading at $3.31 (-10.05%) after investors reacted to its August 14, 2026 second-quarter results. • Q2 loss reached $9.0 million, or $1.31 per...
🔴 Cerenome is trading 9.78% down in pre-market after reporting a $9.0 million second-quarter loss
Cerenome is trading at $3.32, down 9.78% in pre-market on August 17, 2026, after reporting a $9.0 million second-quarter loss and $1.31 loss per share. -...
🔴 Cerenome is trading 10.33% down in after-hours trading after second-quarter loss per share missed estimates
Cerenome is trading at $3.30 (-10.33%) in after-hours trading after its second-quarter loss per share missed estimates. - Cerenome reported a $9.0 million...
Cerenome's second quarter 2026 loss of $9M highlights strategic rebrand and clinical trial expansion
Cerenome reported a significantly widened operating loss for the second quarter of 2026 as the company rebranded from Plus Therapeutics and accelerated its...
Cerenome's Fresh Rebrand Meets a Harsh Reality Check — Can a 28-Person Company Survive a $9 Million Quarterly Burn?
Shares of Cerenome (CNSY) cratered 9.4% to $3.35 after the freshly rebranded brain-cancer diagnostics and therapeutics company posted second-quarter results...